Osteoporosis
Authors: E. Michael Lewiecki
Journal: Annals of Internal Medicine (2011)

In the Clinic5 July 2011OsteoporosisDeborah Cotton, MD, MPH, Darren Taichman, MD, PhD, Sankey Williams, MD, and E. Michael Lewiecki, MDDeborah Cotton, MD, MPH, Darren Taichman, MD, PhD, Sankey Williams, MD, and E. Michael Lewiecki, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-1-201107050-01001 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Osteoporosis is a skeletal disorder characterized by compromised bone strength that predisposes a person to an increased risk for fracture (1). Bone strength is determined by properties that include bone mineral density (BMD), bone geometry (size and shape of bone), degree of mineralization, microarchitecture, and bone turnover. It is a common disease with serious clinical consequences. In the United States, about 44 million people have osteoporosis or osteopenia (low bone mass) that could lead to low-trauma fractures. About 50% of white women and 20% of men will have an osteoporosis-related fracture in their lifetimes. Fractures of the hip and spine ...References1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95. Google Scholar2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Accessed at www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf on 7 March 2011. Google Scholar3. Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75-91. Google Scholar4. U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154:356-64. Google Scholar5. Qaseem A, Snow V, Shekelle P, Hopkins R, Jr., Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680-684. Google Scholar6. World Health Organization. FRAX WHO Fracture Risk Assessment Tool. Accessed at www.shef.ac.uk/FRAX/ on 1 October 2010. Google Scholar7. Recker RR, Davies M, Hinders SM, et al. Bone gain in young adult women. JAMA. 1992;268:2403-8. Google Scholar8. MacKelvie KJ, McKay HA, Petit MA, et al. Bone mineral response to a 7-month randomized controlled, school-based jumping intervention in 121 prepubertal boys: associations with ethnicity and body mass index. J Bone Miner Res. 2002;17:834-44. Google Scholar9. Fuchs RK, Bauer JJ, Snow CM. Jumping improves hip and lumbar spine bone mass in prepubescent children: A randomized controlled trial. J Bone Miner Res. 2001;16:148-56. Google Scholar10. Wolff I, van Croonenborg JJ, Kemper HC, et al. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 1999;9:1-12. Google Scholar11. Kelley GA, Kelley KS, Tran ZV. Exercise and bone mineral density in men: a meta-analysis. J Appl Physiol. 2000;88:1730-1736. Google Scholar12. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713-16. Google Scholar13. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842-56. Google Scholar14. Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev. 2004;CD004526. Google Scholar15. Chapuy MC, Arolt ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-42. Google Scholar16. Dawson-Hughes B, Harris SS, Krall EA, et al. Effects of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med. 1997;337:670-76. Google Scholar17. Qaseem A, Snow V, Shekelle P, Hopkins R, Jr., Forciea MA, Owens DK. Pharmacologic treatment of low BMD or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404-15.] Google Scholar18. Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16. Google Scholar19. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517-23. Google Scholar20. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19:11-18. Google Scholar21. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524-28. Google Scholar22. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-38. Google Scholar23. Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343-49. Google Scholar24. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12. Google Scholar25. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-59. Google Scholar26. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc. 2005;53:1697-704. Google Scholar27. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2003;87:4431-37. Google Scholar28. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010;16:1016-19. Google Scholar29. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-83. Google Scholar30. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376-80. Google Scholar31. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-33. Google Scholar32. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-43. Google Scholar33. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-41. Google Scholar34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA. 1998;280:2077-82. Google Scholar35. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-40. Google Scholar36. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91. Google Scholar37. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy VERT. Study Group. JAMA. 1999;282:1344-52. Google Scholar38. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-49. Google Scholar39. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. Google Scholar40. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809. Google Scholar41. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65. Google Scholar42. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA. 1999;282:637-45. Google Scholar43. Chesnut CH, III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-76. Google Scholar44. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. Google Scholar45. Lewiecki EM. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13:335-45. Google Scholar46. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-89. Google Scholar47. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-94. Google Scholar48. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-38. Google Scholar49. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom. 2003;6:307-14. Google Scholar50. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2009;CD007146. Google Scholar51. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-23.] Google Scholar52. National Committee for Quality Assurance. The state of health care quality. Accessed at www.ncqa.org/portals/0/state%20of%20health%20care/2010/SOHC%202010%20-%20Full2.pdf on 7 March 2011. Google Scholar53. Assessment of fracture risk and its application to screening for postmeno- pausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. Google Scholar54. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAssociation of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 DiabetesVitamin D and Bone Mineral Density in HIV Newly Diagnosed Therapy-Naive Patients Without Any Secondary Causes of OsteoporosisModelling of femur fracture using finite element proceduresOsteoporosis Recovery by Antrodia camphorata Alcohol Extracts through Bone Regeneration in SAMP8 MiceOsteoporosisBoron Containing Nano Hydroxyapatites (B-n-HAp) Stimulate Mesenchymal Stem Cell Adhesion, Proliferation and DifferentiationBone Mineral Density in Young Women With Primary Ovarian Insufficiency: Results of a Three-Year Randomized Controlled Trial of Physiological Transdermal Estradiol and Testosterone ReplacementBone mineral density and the risk of breast cancer: a case-control study of Korean womenDietary Polyphenols, Berries, and Age-Related Bone Loss: A Review Based on Human, Animal, and Cell StudiesAntiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsyThe benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease—chronic kidney disease—mineral and bone disorder: Osteoporosis 5 July 2011Volume 155, Issue 1Page: ITC1-1KeywordsBoneBone mineral densityBone remodelingBone resorptionCalciumExerciseFallsOsteoporosisSpineVitamin D ePublished: 5 July 2011 Issue Published: 5 July 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...